Cipla’s New York plant gets FDA no-action classification
FDA gave Cipla’s InvaGen plant in Hauppauge a No Action Indicated classification after its October 2026 inspection, easing regulatory uncertainty without approving any drug or product.

Stories
U/AUTHOR
5 filings logged
FDA gave Cipla’s InvaGen plant in Hauppauge a No Action Indicated classification after its October 2026 inspection, easing regulatory uncertainty without approving any drug or product.
